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Abstract
Background: Low nutrient environment is a major obstacle to solid tumor growth. However, many tumors have
developed adaptive mechanisms to circumvent the requirement for exogenous growth factors.
Methods: Here we used siRNA interference or plasmid transfection techniques to knockdown or enhance CD317
expression respectively, in mammalian cancer cells, and subjected these CD317-manipulated cells to serum deprivation
to study the role of CD317 on stress-induced apoptosis and the underlying mechanism.
Results: We report that CD317, an innate immune gene overexpressed in human cancers, protected cancer cells
against serum deprivation-induced apoptosis. In tumor cells, loss of CD317 markedly enhanced their susceptibility to
serum deprivation-induced apoptosis with no effect on autophagy or caspase activation, indicating an autophagy- and
caspase-independent mechanism of CD317 function. Importantly, CD317 knockdown in serum-deprived tumor cells
impaired mitochondria function and subsequently promoted apoptosis-inducing factor (AIF) release and nuclear
translocation but had little effect on mitochondrial and cytoplasmic distributions of cytochrome C, a pro-apoptotic
factor released from mitochondria that initiates caspase processing in response to death stimuli. Furthermore,
overexpression of CD317 in HEK293T cells inhibits serum deprivation-induced apoptosis as well as the release and
nuclear accumulation of AIF.
Conclusion: Our data suggest that CD317 functions as an anti-apoptotic factor through the mitochondria-AIF axis in
malnourished condition and may serve as a potential drug target for cancer therapy.
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Background
Hypoxia, low nutrient environments, and exogenous
growth factor depletion are among the most important
challenges that any rapidly growing solid tumor must sur-
mount to survive, grow and metastasize. Serum or growth
factor deprivation can induce apoptosis in normal cells as
well as tumor cells that cannot mount an adaptive response
to it [1–3]. Despite all this, many tumors have developed
adaptive mechanisms to circumvent this requirement for
exogenous growth factors [1]. These adaptive mechanisms
are important for tumor growth and invasion but still
remain unclear, which limits the strategy design for cancer
therapy.
CD317 (also referred as tetherin, BST2, or HM1.24 anti-
gen) is a type II transmembrane glycoprotein with an atyp-
ical membrane topology [4]. It consists of an N-terminal
transmembrane domain, extracellular coiled-coiled domain,
and a C-terminal GPI anchor [4]. This unique topology
gives CD317 viral tethering function [5–8]. As reported,
CD317 inhibits the release of many enveloped viruses from
the surface of infected cells. These include all retroviruses
tested as well as members from seven other families, such
as Hepadnaviridae (Hepatitis B virus), Flaviviridae (Hepa-
titis C virus), Filoviridae (Ebola and Marburg viruses),
Arenaviridae (Lassa fever virus), Herpesviridase (Kaposi’s
sarcoma-associated herpesvirus), Paramyxoviridae (Sendai
virus and Nipah virus), and Rabdoviridae (vesicular
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stomatitis virus) [6, 9–15]. There is a growing literature
demonstrating the importance of CD317 in limiting viral
infection, however, other functions of CD317 such as its
impact on tumorigenesis remain undefined. CD317 ex-
presses in several types of cancers including multiple
myeloma (MM), B cell lymphoma, lung cancer, head and
neck squamous cell carcinomas, endometrial cancer, brain
cancer and bone metastatic breast cancer [9]. Although it
is unclear what function CD317 serves on transformed
cells, it was found that overexpression in breast cancer
cells results in increased migration and proliferation [16].
In addition, CD317 is a potential target for tumor immuno-
therapy. Humanized monoclonal antibody (McAb) against
CD317 showed significant tumor growth inhibition and
prolonged survival in human MM xenograft models and
MM patients, and the antitumor effect of CD317 McAb
were largely mediated by natural killer (NK) cell and mono-
cyte- and macrophage-mediated antibody-dependent cellu-
lar cytotoxicity (ADCC) [17]. In our present study, we
investigated the anti-apoptotic effect of CD317 on several
mammalian cell lines cultured in serum deprivation condi-
tion, and explored the underlying mechanisms.
Methods
Antibodies and reagents
Antibodies used in this study are as follow: monoclonal
rabbit anti-BST-2(Abcam, 1:1000), polyclonal rabbit
anti-Bcl-2 (CST, 1:1000), polyclonal rabbit anti-Caspase-
3 (CTS, 1:1000), monoclonal mouse anti-Caspase-8(1C
12)(CST, 1:1000), polyclonal rabbit anti-Caspase-9 (CST,
1:1000), polyclonal rabbit anti-LC3A/B(CST, 1:1000),
polyclonal rabbit anti-AIF (CST, 1:1000), polyclonal rabbit
anti-COX IV (CST, 1:1000), monoclonal mouse anti-
Lamin A/C(4C11) (CST, 1:1000), monoclonal mouse anti-
cytochrome C (Beyotime Biotech, 1:200), polyclonal mouse
anti-β-Actin and anti-GAPDH (Santa Cruz Biotechnology,
1:8000), HRP-labeled goat anti-mouse and anti-rabbit IgG
(Earthox, 1:10000).
DMEM medium, fetal bovine serum (FBS), penicillin
and streptomycin were purchased from HyClone (Logan,
USA). L-glutamine was purchased from Gibico (CA,
USA). Annexin V-FITC/PI apoptosis detection kit and
was purchased from TransGen Biotech (Beijing, China).
7-AAD viability staining solution was purchased from
BioLegend (San Diego, CA, USA). Nuclear extraction kit
and mitochondria extraction kit were obtained from
Pierce Biotechnology (Rockford, USA). Ac-DEVD-CHO
was purchased from Beyotime Biotech (Nanjing, China).
CD317-specific siRNA (named as siR317) and Normal
Control siRNA (name as NC) were synthesized by Gene-
Pharma (Shanghai, China). The sequences of the siRNA
targeting human CD317 were 5-CCAGGUCUUAAGCGU
GAGAdTdT-3 and 5-UCGCGGACAAGAAGUACUAdTd
T-3 (corresponding to base pairs 432–450 and 452–470 of
the human CD317 sequence, respectively) [18], and the se-
quences of murine CD317-specific siRNA were 5-GGGU
UACCUUAGUCAUCCUdTdT-3 and 5-GCUUGAGAAU
GAAGUCACGdTdT-3 (corresponding to base pairs 126–
144 and 379–397 of the murine CD317 sequence, respect-
ively), the NC siRNA (5-UUCUCCGAACGUGUCAC-
GUdTdT-3) was used as negative control. MigR1-CD317
plasmid (named as plasCD317) was constructed in our lab.
Briefly, the full length of human CD317 CDS was cloned
from Jurkat cells by RT-PCR using specific primers, digested
with Bgl II and Xho I, then subcloned into the expression
vector MigR1 and sequenced.
Cells and transfection
Hela (an epithelial cell line from female cervical cancer),
SK-OV-3(a human ovarian cancer cell line), MCF-7 (a lu-
minal human breast cancer cell line), HepG2 cells(a hepato-
cellular carcinoma cell line), sp2/0 cells (a mouse myeloma
cell line), U266(a human myeloma cell line) and HEK293T
(a CD317 negative human embryonic kidney cell line) were
obtained from ATCC or Cell bank, Chinese academy of
sciences(Shanghai, China) and routinely culture in DMED
medium or RPMI-1640 medium supplemented with 10 %
fetal bovine serum, 2 mM L-glutamine, 100 U/mL penicil-
lin, and 10 mg/mL streptomycin. All cultures were main-
tained in a humidified 5 % CO2 incubator at 37 °C, and
routinely passaged when 80–90 % confluent.
The CD317-positive cells were transfected with NC
(named as NC cells) or siR317 (named as siR317 cells),
while the HEK293T cells were transfected with MigR1 or
plasCD317, respectively. All transfections were performed
using Lipofectamine 3000 (Invitrogen, USA) or Gene
Pulser Xcell (BioRad, USA) according to the manufac-
turer’s instructions.
After the transfection, cells were cultured in normal or
serum deprivation condition for subsequent experiments.
FACS analysis for apoptosis
After transfection, cells were cultured in normal or serum
withdrawal condition for another 48 h and then stained
with 7-AAD or double-stained with Annexin V-FITC and
propidium iodide (PI) using an apoptosis detection kit for
flow cytometry analysis. All samples were analyzed using
flow cytometer (FACS Canto II, BD).
JC-1 assay for MMP
Mitochondrial membrane potential (MMP,ΔΨm) was eval-
uated by JC-1 reduction according to the manufacturer’s
instructions. After indicated treatment and wash, cells were
incubated with 2.5 μM JC-1 at 37 °C for 30 min and then
quantified using flow cytometer (FACS Canto II, BD).
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Immunofluorescence and microscopy
Hela cells mounted on glass slides were fixed with 4 %
paraformaldehyde (PFA) for 20 min at room temperature
and then permeabilized with 0.1 % Triton X-100 for
another 20 min. Cells were blocked with goat serum for
20 min at room temperature and then incubated with pri-
mary antibody (polyclonal rabbit anti-AIF, 1:1000) at 4 °C.
After overnight incubation, cells were further stained with
rhodamine-conjugated goat anti-rabbit IgG (Molecular
Probes), and 4, 6-diamino-2-phenylindole (DAPI, Roche)
and analyzed on an optical microscopy (Olympus IX71,
Tokyo, Japan). 10–15 high-powered fields were evaluated,
and fixed fluorescence images were analyzed by Image-
Pro Plus software (Media Cybernetics, Silver Spring, MD).
Cytoplasmic and nuclear protein extraction
Cell cytoplasm and nucleus protein were collected with
NE-PER Nuclear and Cytoplasmic Extraction Reagents
(Pierce). In brief, cells were washed with cold PBS and
fully suspended in ice-cold CER I by vortex on the high-
est setting for 15 s, followed by incubation on ice for
10 min. Homogenates were added ice-cold CER II, incu-
bated on ice for 1 min and then centrifuged at 16,000 g
for 5 min at 4 °C. The supernatants (cytosol) were col-
lected and the pellets were suspended in ice-cold NER
and incubated on ice for 40 min, vortex for 15 s every
10 min. The lysates were again centrifuged at 16,000 g
for 5 min, and the supernatants (nucleus) were collected.
The distributions of protein in cytosol and nucleus were
analyzed by western blot.
Mitochondria isolation
Isolation of mitochondria was performed using mitochon-
dria isolation kit (Pierce). Briefly, 1 × 107 cells were sus-
pended in 800 μL Reagent A and incubated on ice for
exactly 2 min, then were added 10 μL Reagent B followed
with another incubation on ice for 5 min. After that,
800 μL Reagent C was added and then the mixture was
centrifuged at 700 g for 10 min at 4 °C. The supernatant
was transferred to a new 2.0 mL tube and centrifuged at
12,000 g for 15 min at 4 °C to obtain the mitochondria. At
last, the isolated mitochondria were lysed in RIPA buffer
containing 1.0 mM PMSF (Beyotime, China) to extract
protein for further analysis.
Immunoprecipitation
Hela cells were cultured in normal or serum-deprivation
condition for 24 h, cell lysates were prepared and immuno-
precipitated with anti-CD317 or control Ig. The precipitates
and lysates were subjected to Western blotting with anti-
bodies for the indicated antigens.
Western blot
Cells were washed with PBS and lysed with RIPA buffer
supplemented with 1.0 mM PMSF. After 15-min incuba-
tion on ice, lysates were centrifuged at 12,000 rpm for
20 min at 4 °C. The supernatant was collected, and the
protein concentration was measured by bicinchoninic acid
(BCA) assay (Beyotime, China). Whole cell lysates (25–
50 μg of denatured protein) were separated on a 4–20 %
gradient SDS polyacrylamide gel and then transferred to a
PVDF membrane (Millipore). The membrane was blocked
for 1 h at room temperature in PBST, pH 7.4 (PBS with
0.1 % Tween-20) with 5 % BSA. After washing, the mem-
brane was incubated with primary antibodies overnight at
4 °C, followed by extensive washing and incubation with
HRP-conjugated secondary antibodies. At last, protein was
visualized by an enhanced chemiluminescense detection
kit (Millipore, USA). After stripping, the blot was reprobed
with β-Actin or GAPDH antibody (Santa Cruz) to ensure
equal loading of total protein.
Statistical analysis
All data represent at least 3 independent experiments and
are expressed as mean ± SEM. Statistical comparisons
were made using Student’s t-test. P < 0.05 was considered
statistically significant.
Results
CD317 knockdown sensitizes tumor cell to serum
deprivation-induced apoptosis
FBS is the most widely used growth supplement in cell cul-
ture medium, which provides nutrients and growth factors
for cell proliferation. Researchers often use FBS depletion
as a means to emulate the tumor microenvironment of
some cancers. We, therefore, investigated involvement of
CD317 in apoptosis during serum deprivation. As shown in
Fig. 1a, CD317 silencing did not affect apoptosis in Hela
cells cultured in normal medium (Ctrl group, NC vs
siR317, 15.29 ± 0.75 % vs 16.06 ± 0.46 %, P = 0.4036), but
markedly enhanced apoptosis during serum deprivation
(FBS-free group, NC vs siR317, 14.29 ± 0.61 % vs 24.40 ±
1.33 %, P < 0.0001). Considering that tumor necrosis factor
(TNF)-related apoptosis-inducing ligand (TRAIL) is a
promising anticancer agent that can induce apoptosis in a
wide range of cancers, and the translation of TRAIL into
the clinic has been confounded by TRAIL-resistant cancer
cell populations [19], we investigated whether CD317 in-
volves in TRAIL-resistant mechanisms. As it is shown in
the TRAIL group of Fig. 1a, CD317 did not affect TRAIL-
induced apoptosis (NC vs siR317, 20.76 ± 0.84 % vs 21.57 ±
0.80 %, P = 0.4972). In order to further confirm our obser-
vation in a broad spectrum of cancer calls, we also exam-
ined the other four cell lines in the same experimental
condition. We found a consistent effect of CD317 on apop-
tosis in MCF-7 (Fig. 1b), SK-OV-3 cells (Fig. 1c), HepG2
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cells (Additional file 1: Figure S1), U266 cells (Additional
file 1: Figure S2) and sp2/0 cells (Additional file 1: Figure
S3). These data suggested that CD317 has a function inde-
pendent of TRIAL and works as an anti-apoptotic factor
making the CD317-bearing tumor cells more resistant to
serum deprivation-induced apoptosis.
CD317 knockdown enhances apoptosis through autophagy-
independent manner
Starvation induces a vigorous autophagic response to
enhance cellular survival, whereas nutrient and serum
supplementation inhibit autophagy and induce an in-
tensive transcriptional burst that enables cellular prolif-
eration [20]. To determine whether autophagy flow is
responsible for the CD317-mediated apoptosis resist-
ance, we subjected Hela cells to serum withdrawal for
48 h in the presence of either 3MA or rapamycin. As
shown in Fig. 2, inhibition of autophagy by 3MA led to
an increased apoptosis, while treatment with autophagy
agonist (rapamycin) had no significant effect in serum
deprivation-induced apoptosis in both NC and siR317
cells. However, neither 3MA nor rapamycin abrogated
Fig. 1 CD317 knockdown enhances serum deprivation-induced apoptosis in tumor cells. (a) Representative graphs (left panel) and statistical analysis
(Right panel) of cell apoptosis determined by flow cytometric evaluation in Hela cells. In brief, 36 h post transfection,cells were cultured in the indicated
conditions for another 48 h and double stained with annexin V and PI to detect cell apoptosis. ***P < 0.001. (b) and (c) Representative results obtained
from MCF-7 and SK-OV-3, respectively. Cells were treated using the same method described above. *P < 0.05, **P < 0.005
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the anti-apoptotic effect of CD317. In addition, we dy-
namically monitored autophagosome formation by im-
munofluorescence in Hela cells cultured in serum-free
medium, and found no obvious difference between NC
and siR317 group (data not shown). In line with this obser-
vation, the level of cleaved LC3, a biochemical marker for
autophagic cells, was not affected by CD317 silencing both
in normal and serum-free condition (Fig. 3). These results
suggested that autophagy flow dose not directly contribute
to CD317-mediated apoptosis resistance in serum-deprived
tumor cells.
CD317 knockdown enhances apoptosis through caspase-
independent manner
To study whether CD317 affect apoptosis through cas-
pase processing axis, we compared the level of cleaved
caspase between NC and siR317 cells. However, no sig-
nificant difference in the expression of cleaved caspase
8, 9 and 3 was observed between NC and siR317 cells
in the presence or absence of FBS, indicating that
CD317 silencing cannot influence caspase cascade
(Fig. 3a). In accordance with that, treatment with Ac-
DEVD-CHO, a specific inhibitor for caspase 3, signifi-
cantly reduced serum deprivation-induced apoptosis
but failed to abrogate the different apoptosis levels be-
tween NC and siR317 cells (Fig. 3b, c, Ac-DEVD-CHO
group, NC vs siR317, 11.37 ± 0.44 % vs 21.10 ± 3.18 %,
P = 0.0386). These data suggested that CD317 prevents
cells apoptosis without affecting caspase cascade, which
can partially explain the absence of CD317 in the regu-
lation of TRAIL-induced apoptosis, an extrinsic apop-
totic pathway mainly depend on caspase activation.
Fig. 2 CD317 knockdown enhances apoptosis through autophagy-independent manner. (A) Representative graphs (left panel) and statistical analysis
(Right panel) of cell apoptosis determined by flow cytometric evaluation in Hela cells. Similarly, Cells transfected with NC or siR317 were cultured in the
presence or absence of 5 mM 3MA, or 100 nM Rapacycin. After a 48 h-incubation, cells double stained with annexin V and PI to detect cell apoptosis.
**P < 0.005, ***P < 0.001
Fig. 3 CD317 knockdown promotes cell apoptosis through caspase-independent manner. a Blot image represented 1 of 3 independent experiments
performed in Hela cells. NC and siR317 cells were cultured in the presence or absence of FBS and harvested at 24 h. Whole cell lysates were prepared
and analyzed for LC3, Caspase 8, 9, 3 and CD317. β-actin served as an equal loading control. b Representative graphs of cell apoptosis determined by
flow cytometric evaluation in Hela cells. NC and siR317 cells were cultured in FBS-free medium with or without 40 μM Ac-DEVD-CHO (a specific
inhibitor for Caspase 3) and harvested at 48 h for apoptosis analysis. c Quantitative analysis of cell apoptosis as shown in B. *P < 0.05
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CD317 Knockdown impairs mitochondria function
resulting in AIF release and accumulation in nucleus
Many studies have shown that cells usually suffered mito-
chondria dysfunction during serum deprivation, exerting
low mitochondrial membrane potential (MMP, ΔΨm) and
high permeability, which further caused the release of AIF,
a mitochondrial protein that translocated to the nucleus to
induce chromatin condensation in a caspase-independent
manner [21]. To address whether CD317 suppressed apop-
tosis of serum-deprived cells through mitochondria-AIF
axis, we compared the level of MMP between NC and
siR317 cells by JC-1 staining. JC-1 could aggregate in mito-
chondria and present high red fluorescence in normal cells,
whereas exists in the cytoplasm as a monomer emitting
green fluorescence in the cells to die. Flow cytometry ana-
lysis showed that CD317 silencing had little effect on mito-
chondrial function in normal condition but markedly
promoted serum deprivation-induced MMP loss as ob-
served by a decrease in JC-1 ratio (red/green fluorescence,
FBS-free group, NC vs siR317, 1.61 ± 0.098 vs 1.22 ± 0.097,
P = 0.0488) as well as an increase percentage of cells with
low MMP (FBS-free group, NC vs siR317, 12.60 ± 1.23 % vs
20.60 ± 2.52 %, P = 0.0464) (Fig. 4a–b). These results indi-
cated that CD317 silencing promoted mitochondrial
depolarization in serum-deprived tumor cells. Considering
that AIF would be released from mitochondria after mito-
chondrial depolarization and translocate into nucleus to
cause cell death, we analyzed the protein distribution of
AIF in mitochondria and nucleus. As shown in Fig. 4c, the
nuclear level of AIF was significantly higher in serum-
deprived siR317 cells than that in the NC counterpart. This
nuclear accumulation was accompanied by a decline in
mitochondrial distribution, suggesting that CD317 knock-
down in serum-deprived cells enhanced AIF release and
Fig. 4 CD317 regulates serum deprivation-induced apoptosis through mitochondria-AIF axis. a Flow cytometry in combination with JC-1 staining
performed in Hela cells. NC and siR317 cells were cultured in FBS-containing or FBS-free medium. After a 24 h-incubation, cells were harvested
and subjected to JC-1 staining following flow cytometry for MMP dection. Red characters indicated the percentage of cells with low ΔΨm, while
blue indicating the JC-1 ratio (red/green fluorescence). b Quantitative analysis of the percentage and JC-1 ratio shown in A. *P < 0.05. c Subcellular
distribution of cytochrome c (CYC) and AIF in Hela cells detected by western blot. In brief, NC and siR317 cells were cultured in the presence or
absence of FBS for 24 h and collected for subcellular fractionation extraction. Lamin A/C, GAPDH, and COX IV served as the loading control for
nuclear, cytoplasmic, and mitochondrial protein, respectively. d Representative microscopy of immunostained AIF in Hela cells. NC and siR317 cells
were harvested after a 24-h incubation with or without FBS, and then fixed and immunostained for AIF (red) and nucleus (blue). Pictures were
taken with a fluorescence microscope. Fifteen microscopic fields per culture were evaluated in a blind manner. Colocalization of AIF and nucleus
was analyzed by ImagePro Plus solfware. Pearson’s correlation coefficient (R) was used as a measure of colocalization of Red signals with blue
signals. Correlation plot was corresponding to the left figure. The mean correlation coefficient value (R) ± SEM of at least fifteen fields is shown on
the plots. Scale bar: 20 μm
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translocation into nucleus. To address the specificity of this
observation, the distribution of cytochrome c in cytoplasm
and mitochondria was also detected by western blotting. As
shown in Fig. 4c (bottom panel), CD317 knockdown did
not cause a visible change in the distribution of cytochrome
c in cells cultured in the absence or presences of FBS.
Furthermore, microscopy of immunostained AIF demon-
strated as well that AIF accumulated more obviously within
the nucleus of serum-deprived siR317 cells than that in NC
cells (Fig. 4d) as observed by an increase co-location ratio
(R value, NC vs siR317, 0.44 ± 0.079 vs 0.69 ± 0.034, P =
0.0062). Thus, these results suggested that CD317 knock-
down significantly enhances serum deprivation-induced
apoptosis through mitochondria-AIF axis.
To further investigate the resistant mechanism of CD317
in AIF release and nuclear accumulation, we try to find the
binding partners of CD317 by immunoprecipitation. As
shown in Additional file 1: Figure S4, CD317 did not bind
with either AIF or Calpain 1, a Ca2+-dependent neutral
cysteine protease that colocalizes with AIF and promotes
AIF maturation and release [22], in both normal and
serum-free condition. These data suggest that CD317 mod-
ulates AIF release without direct interaction with AIF or
Calpain 1.
CD317 overexpression inhibits serum deprivation-induces
apoptosis in HEK293T cells
To further verify the anti-apoptotic role of CD317, we
forced CD317 expression in HEK293T (CD317-negative
cells) and detected its influence on apoptosis. Consistent
with our previous observations, CD317 overexpression did
not affect apoptosis of HEK293T cells cultured in normal
medium (Ctrl group, MigR1 vs plasCD317, 2.11 ± 0.24 % vs
2.33 ± 0.23 %, P = 0.5403), but markedly suppressed the
apoptosis of those cultured with serum deprivation (Fig. 5a,
FBS-free group, MigR1 vs plasCD317, 13.17 ± 1.68 % vs
4.28 ± 0.25 %, P = 0.0063). In addition, we found that
CD317 overexpression significantly inhibited the release
and nuclear translocation of AIF in serum-free culture con-
dition (Fig. 5b, further confirmed that CD317 functions as
an anti-apoptotic factor through AIF-mediated manner.
Discussion
In this study, we conducted in vitro experiments to investi-
gate the role of CD317 in five human cell lines and one
mouse cell line. Our data demonstrated that CD317 knock-
down in either human or mice tumor cells significantly
augmented the susceptibility of CD317-bearing tumor cells
to serum deprivation-induced apoptosis (Fig. 1, Additional
file 1: Figure S1, Additional file 1: Figure S2 and Additional
file 1: Figure S3). Moreover, over-expression of CD317 in
the CD317-negative cells endowed the cells a markedly in-
creased resistance to the serum deprivation-induced apop-
tosis (Fig. 5a). These findings revealed a novel function of
CD317 in cancer biology and led us to explore the mecha-
nisms underlying this intriguing phenomenon.
CD317 is well documented as a cellular protein which
inhibits retrovirus infection by preventing the diffusion of
virus particles after budding from infected cells [23]. It has
also been identified as the protein that help stabilize lipid
rafts by joining nearby lipid rafts to form a cluster, and
been predicted to be involved in cell adhesion and cell
migration [24]. In the fields of oncology, CD317 has been
identified to be overexpressed on several lines of cancer
cells [25, 26], and some of its effects on tumors have been
reported. In human, overexpression of CD317 has been
associated with poor survival of patients with several types
cancers [27]. In mice, CD317 expression in breast tumor
Fig. 5 CD317 overexpression inhibits serum deprivation-induced apoptosis in AIF-related manner. a. Representative graphs (left panel) and statistical
analysis (Right panel) of cell apoptosis determined by flow cytometric evaluation in HEK293T cells. In brief, 36 h post transfection,cells were cultured in
the indicated conditions for another 48 h and stained with 7-AAD to detect cell apoptosis. **P < 0.005. b. Subcellular distribution of AIF in HEK293T cells
was detected by western blot. In brief, MigR1 and plasCD317 cells were cultured in the presence or absence of FBS for 24 h and collected for total
protein or subcellular fractionation extraction. Lamin A/C, β-Actin, and COX IV served as the loading control for nuclear, total, and mitochondrial
protein, respectively
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is associated with tumor size, tumor aggressiveness, and
host survival. Knockdown of CD317 in cancer cells de-
creases metastases to the lung and other distal sites tumor
mass [16]. In vitro studies showed that cells with
suppressed CD317 have reduced adhesion, anchorage-
independent growth, migration, and invasion [16]. Our
new finding of the anti-apoptosis function displayed by
the CD317-bearing cells in serum-free culture condition
could partially reveal the underlying mechanisms of those
published observations. Intriguingly, the published report
showing that, in two-dimensional culture, mice 4 T1 cells
but not E0771 cells with suppressed CD317 expression
had higher viability as measured by MTTassay. Therefore,
the authors believed that cell viability may not be impli-
cated in the role of CD317 in cancer cell behavior [16].
This is obviously not in line with our observations. The
discrepancy may possibly, although not exclusively, be
attributable to the differences in experimental design, as it
was shown in our data that the effect of CD317 was
observed in only the serum-deprived rather than the
normal culture condition.
Considering that several groups have discovered that
CD317 can activate NF-kB, a transcriptional activator that
leads to the rapid expression of proteins involved in cell
survival [28], we added TRAIL in the functional assay of
CD317. As shown in Fig. 1, TRAIL-induced apoptosis was
not affected by CD317-silencing, implying the absence of
CD317 in TRIAL-mediated extrinsic apoptotic pathway. To
further understand how CD317 endows the cells with the
anti-apoptotic function, we tested whether autophagy flow
is responsible for the CD317-mediated apoptosis resistance.
As shown in Fig. 2, treatment with autophagy agonist had
no significant effect on both NC and siR317 cells to serum
deprivation-induced apoptosis. Moreover, neither agonist
nor inhibitor of autophagy could abrogate the anti-
apoptotic effect of CD317, and the level of cleaved LC3 was
not affected by CD317 silencing both in normal and
serum-deprived condition (Fig. 3). These results suggested
that autophagy flow dose not directly contribute to anti-
apoptosis function of CD317. Then we turned to examine
whether CD317 affect apoptosis through caspase cascade
(caspase-8/-3 or caspase-9/-3 axis). We compared the level
of cleaved caspases between NC and siR317 cells, and ob-
served no significant difference in the expression of cleaved
caspase-8, -9 and -3, indicating that CD317-knowdown has
no significant influence on these caspase cascades (Fig. 3a).
In accordance with this, treatment with caspase-3 specific
inhibitor significantly reduced serum deprivation-induced
apoptosis but failed to abrogate the different apoptosis
levels between NC and siR317 cells (Fig. 3b, c, Ac-DEVD-
CHO group), suggesting that both capase-dependent and
-independent pathways are involved in the serum-deprived
apoptosis, while the anti-apoptotic function of CD317 may
be independent of caspase cascade.
It is known that mitochondria damage results in the
release of pro-apoptotic protein such as cytochrome c and
AIF, which may trigger caspase-dependent or caspase-
independent cell death [29, 30]. To get further insights
into the pathway through which CD317 plays its anti-
apoptotic role, we examined the pro-apoptotic factor AIF
by comparing the level of MMP between the untreated
and 317 knowdown cells, and found that CD317-silencing
in serum-deprived cells enhanced MMP loss and AIF re-
lease. In addition, a translocation of AIF into nucleus was
also observed. This nuclear accumulation was accompan-
ied by a decline in mitochondrial distribution, indicating
that CD317 knockdown in serum-deprived cells en-
hanced AIF release and translocation into nucleus.
These results suggested that CD317 may protect cells
from serum deprivation-induced apoptosis through
AIF-mediated caspase-independent cell death pathway.
Interestingly, we observed that CD317 knockdown sig-
nificantly enhanced AIF release with little effect on the
subcellular distribution of cytochrome C (Fig. 4c). To clar-
ify the mechanism underlying this observation, we tried to
identify the direct target molecule for CD317. Considering
the published evidence showing that mitochondrial cal-
pain 1, a Ca2+-dependent neutral cysteine protease, can
colocalize with AIF [22], we speculated that AIF or
Calpain 1 may be the binding partner of CD317 and tried
to confirm this assumption by Co-IP, but as shown in
Additional file 1: Figure S4, CD317 did not bind with
either AIF or Calpain 1 in both normal and serum-free
condition. Further investigations are thus needed to eluci-
date the bridging molecules between CD317 and AIF.
Cancer has become a major public health problem over
the world due to its increasing incidence and mortality, as
well as limited therapy strategies [31, 32]. Over the past
two decades, gene therapy, mediated by viral and non-viral
vectors, has been developed as a promising pharmaco-
logical approach to provide potential treatment options for
a variety of cancers [33]. A successful cancer gene therapy
requires an appropriate gene which displays selective tox-
icity toward tumor cells without eliciting harmful effects in
normal cells or tissues [34]. CD317 was dramatically upreg-
ulated in many tumor cells and involved in tumor growth
and metastasis [9, 35]. In this study, we further uncover the
anti-apoptotic role and mechanism of CD317 in serum-
deprived tumor cells, strongly suggesting that CD317 may
be an appropriate target for tumor therapy. Two aspects
described as follows can further explain this issue: 1) As we
known, tumors may experience malnutrition during the
course of their malignant progression, or following the
treatments that disrupt tumor vasculature and lead to the
stress of prolonged serum growth factor deprivation, and
adaptation to such unfavorable conditions is crucial for
tumor survival, growth and metastasis [1]. In this study, we
confirmed that CD317-silencing increased the susceptibility
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of tumor calls to apoptosis, and importantly, this effect of
CD317-silencing was only observed in serum-deprived
cells, implying that gene interference targeting CD317
might be used as a combined approach for the antiangio-
genic tumor therapies; 2) One of the major challenges in
cancer therapy is that many tumor cells carry mutations
in key apoptotic genes such as p53, bcl family proteins or
those affecting caspase signaling, thus making traditional
chemotherapeutic agents ineffective. The triggering of
caspase-independent death pathways, therefore, has be-
come an attractive alternative approach to eradicating
tumor cells [30]. The results of this study as summarized
in our model (Fig. 6.) reveal the role of CD317 in protect-
ing tumor cells from nutrient deficient-induced apoptosis
and the mechanism that CD317 plays an inhibitory role in
the mitochondria-AIF axis, suggesting that CD317 silen-
cing could be a considerable approach for combined
cancer therapies. Recently, Zheng Hu et al reported low-
intensity ultrasound combined with 5-FU produced much
enhanced synergistic anti-tumor effects via enhanced
mitochondria-cytochrome c-caspase cascades [36]. How-
ever, the anti-tumor effects could only be partially rescued
by pan-caspase inhibitor, strongly suggesting that another
mitochondrial pro-apoptotic factor such as AIF may be in-
volved in this process. Thus, CD317 interference may
further enhance US + 5-FU treatment-mediated anti-
tumor effects through promoting AIF release and nuclear
accumulation.
Conclusion
Taken together, our data for the first time revealed that
under a nutrient deficient condition, CD317 functions as
an anti-apoptotic factor through AIF-mediated caspase-
and autophagy-independent manner and may serve as a
target for the development of new therapeutics for
CD317-positive cancers.
Additional file
Additional file 1: Supporting Online Material for “CD317 Promotes the
survival of cancer cells through apoptosis-inducing factor”. (DOCX 550 kb)
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